This Market Spotlight report covers the Hodgkin’s Lymphoma market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence and prevalence forecast, probability of success, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Head and neck cancers (HNCs) are defined as any cancer that begins in cells of the oral cavity, pharynx, nose, sinuses, or salivary glands. These cancers are grouped together due to historical similarities in etiology, disease presentation, and manifestation. The vast majority of these cases (90%), collectively referred to as head and neck squamous cell carcinomas (HNSCCs), appear in squamous epithelial cells lining the mucous membranes of these regions. The exception to this is salivary gland cancer, which can appear in any of the salivary glands’ diverse cell types.
Multiple myeloma (MM) is a hematological malignancy characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. The disease represents approximately 1% of all cancers, and 10% of hematological cancers. The hallmarks of MM are high levels of monoclonal (M-) protein, high levels of clonal plasma cells in the bone marrow, and organ damage.
Stomach or gastric cancer (GC) refers to any cancer arising in the lining of the stomach. The vast majority (95%) of these cancers are adenocarcinomas, and can be further grouped by anatomic origin. The clearest etiological distinction exists between adenocarcinomas of the gastric cardia (the anterior edge of the stomach surrounding the entry point of the esophagus), and those arising in the other anatomical subsites of the stomach – the fundus, body, pylorus, and the antrum. In most cases, gastric adenocarcinomas will begin in the muscularis mucosae and submucosa, then invading deeper lamina of the gastric wall.
Tumor lysis syndrome (TLS) comprises a group of metabolic disturbances that result from either chemotherapy or spontaneously induced tumor cell death. The release of intracellular components, including nucleic acids, electrolytes, and proteins, into the systemic circulation is triggered by tumor cytotoxicity. This may result in the development of metabolic abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinically, this can lead to effects on multiple organs such as cardiac arrhythmias, seizures, and acute kidney injury.
This Market Spotlight report covers the Waldenström Macroglobulinemia (WM) market, comprising key marketed and pipeline drugs, probability of success, clinical trials, regulatory events, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.
Liver cancers can be differentiated based on the cell types they affect. The most common form of liver cancer is hepatocellular carcinoma (HCC), which accounts for 80–90% of liver cancer cases. HCC affects hepatocellular cells, or hepatocytes, which are the most abundant cell type in the liver and are responsible for the liver’s primary functions, such as bile production, protein synthesis, and detoxification. This differentiates HCC from other types of liver cancer such as cholangiocarcinoma, which affects the epithelial cells lining the bile ducts, and angiosarcoma, which affects the endothelial cells lining blood vessels of the liver.
Ovarian cancer is defined as a group of tumors that originate in the ovaries. Most ovarian cancers are epithelial carcinomas which begin in the tissue surrounding the ovary. Other less common types of ovarian tumors include primary peritoneal, fallopian tube, and malignant germ cell tumors. Ovarian cancer is the fourth most common cancer among women, and is the leading cause of gynecological cancer-related death in women.
This Market Spotlight report covers the Uterine Cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Gastrointestinal Stromal Tumor (GIST) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and drug-specific revenue forecasts.
This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Glioblastoma market, comprising key marketed and pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue.
The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.
This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!